On page 289, Figure 4 and Notes should read as follows:
Endostatin inhibits the expression of α-Sma, rhoa, and rOCK1 at mrNa level. Notes: Transcript levels of α-Sma, rhoa, and rOCK1 were analyzed by rT-PCr (A-C). Endostatin significantly suppressed the expressions of α-Sma, rhoa, and rOCK1 at mrNa level in HSC-T6 cells. Data are expressed as mean ± SD. *P,0.05, **P,0.01 (n=3 per group). Abbreviations: α-Sma, α-smooth muscle actin; GaPDH, glyceraldehyde 3-phosphate dehydrogenase; HSC, hepatic stellate cell; rhoa, ras homolog gene family, member a; rOCK1, rho-associated protein kinase 1; rT-PCr, real-time PCr. 
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